Health Services Research/Global Oncology
Radiation and Cancer Biology
AMA PRA Category 1 Credits 1.25
CAMPEP Credits: 1.25
MDCB Credits: 1.25
Nima Nabavizadeh, MD
Oregon Health & Science University
Portland, OR
A variety of blood-based cancer screening tests assessing circulating tumor analytes in peripheral blood (including multi-cancer detection (MCD) and single cancer screening tests) are currently being developed with the potential to disrupt current screening paradigms. In this educational session, we highlight the developing technologies, early results from clinical studies testing the efficacy of blood-based genomic tests for cancer screening as well as discuss a proposed professional expansion of the radiation oncology practice relating to the diagnostic workup of individuals who undergo blood-based screening. As blood-based genomic tests for screening have the potential to dramatically alter current paradigms and downstream cancer therapy, it is imperative for radiation oncologists to be aware of important clinical studies, key questions that remain for assessment and regulation, and their potential impact on the field of radiation oncology. All moderators and speakers for this session are ASTRO members/radiation oncologists who have specific interest and experience in the development of blood-based genomic tests for cancer screening.
Speaker: Nima Nabavizadeh, MD – Oregon Health & Science University
Speaker: Scott Bratman, MD, PhD – Princess Margaret Hospital
Speaker: Caitlin Schonewolf, MD, MS – University of Michigan
Speaker: Sana Raoof, MD, PhD – Memorial Sloan Kettering Cancer Center
Speaker: Nima Nabavizadeh, MD – Oregon Health & Science University
Speaker: Nima Nabavizadeh, MD – Oregon Health & Science University